Compare State Street SPDR S&P Biotech ETF (XBI) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Yum! Brands, Inc. — how do they compare? State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B), while Yum! Brands, Inc. trades at $144.82 (market cap $39.02B). The key difference: Yum! Brands, Inc. is far larger — about 3.9× State Street SPDR S&P Biotech ETF's market cap, and Yum! Brands, Inc. pays a 2.1% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR S&P Biotech ETF for 38 Days and Yum! Brands, Inc. for 132 Days on average.
| XBI | YUM | |
|---|---|---|
Market Cap | $10.11B | $39.02B |
Volume | 12,903,266 | 2,597,636 |
Sector | Broad Market / Factor | Consumer Cyclical |
52-Week High | $169.55 | $168.16 |
52-Week Low | $104.99 | $135.77 |
Typical Hold Time | 38 Days | 132 Days |
Enterprise Value | — | $50.63B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
YUM trades at $143.00, up 1.89% over 24 hours, with a bullish technical signal and strong support at $141. Revenue has grown from $6.8B in 2022 to $8.2B in 2025, with net income reaching $1.56B. Recent news highlights KFC's new Open House restaurant concept in Texas, testing expanded menus and customer experiences.
The outlook remains positive with a consensus price target of $170.44, though risks include high debt levels and competitive pressures. Earnings have beaten expectations in two of the last three quarters, with Q3 2026 results pending. Analyst sentiment is mixed with 39.22% buy ratings, 54.9% hold, and 5.88% sell.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
